1. A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue), phase I (purple), and preclinical (gray).
A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue), phase I (purple), and preclinical (gray). B, Top inhibitors of Ba/F3 transformed with CD74–NTRK1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue), phase I (purple), and preclinical (gray).
Curtis R. Chong et al. Clin Cancer Res 2017;23:
©2017 by American Association for Cancer Research